Apart from their role in diabetes mellitus control or in all spectrum heart failure, sodium–glucose cotransporter-2 inhibitors (SGLT2i) may play a role in the atherosclerosis reversal on a mice model by the inhibitory effect on IL-1β through ROS/NLRP3/caspase-1 signaling (103). This evidence concerns the gene NLRP3 and atherosclerosis.